Insulet Corporation (PODD)

Market Cap	10.80B
Revenue (ttm)	1.47B
Net Income (ttm)	62.90M
Shares Out	69.82M
EPS (ttm)	0.90
PE Ratio	171.86
Forward PE	79.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33
Open	155.01
Previous Close	155.70
Day's Range	154.11 - 157.16
52-Week Range	154.11 - 335.91
Beta	0.81
Analysts	Buy
Price Target	287.13 (+85.64%)
Earnings Date	Nov 2, 2023

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorpo...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 2,600
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD

Financial Performance

In 2022, Insulet's revenue was $1.31 billion, an increase of 18.79% compared to the previous year's $1.10 billion. Earnings were $4.60 million, a decrease of -72.62%.

Analyst Forecast

According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $287.13, which is an increase of 85.64% from the latest price.

Price Target

$287.13

(85.64% upside)

Analyst Consensus: Buy